文献检索
文档翻译
深度研究
Zotero 插件
邀请有礼
套餐&价格
历史记录
Suppr
超能文献
应用&插件
文献AI研究员
20分钟写一篇综述，助力文献阅读效率提升50倍。
立即体验
用中文搜PubMed
大模型驱动的PubMed中文搜索引擎
马上搜索
文档翻译
学术文献翻译模型，支持多种主流文档格式。
立即体验
应用&插件
Zotero 插件
浏览器插件
Mac 客户端
Windows 客户端
微信小程序
定价
高级版会员
购买积分包
购买API积分包
服务
文献检索
文档翻译
深度研究
API 文档
关于我们
关于 Suppr
公司介绍
联系我们
用户协议
隐私条款
关注我们
Suppr 超能文献
核心技术专利：
CN118964589B
侵权必究
粤ICP备2023148730 号-1
Suppr @ 2025
相似文献
1
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers.
Nat Commun. 2015 Sep 22;6:8305. doi: 10.1038/ncomms9305.
2
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
Sci Transl Med. 2014 Feb 19;6(224):224ra26. doi: 10.1126/scitranslmed.3007947.
3
Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
Clin Cancer Res. 2014 Jul 15;20(14):3775-86. doi: 10.1158/1078-0432.CCR-13-2181. Epub 2014 May 8.
4
Epidermal growth factor receptor: pathway, therapies, and pipeline.
Clin Ther. 2013 Sep;35(9):1282-303. doi: 10.1016/j.clinthera.2013.08.007.
5
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.
Cancer Res. 2007 Mar 15;67(6):2643-8. doi: 10.1158/0008-5472.CAN-06-4158.
6
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Cancer Res. 2004 Aug 1;64(15):5355-62. doi: 10.1158/0008-5472.CAN-04-0562.
7
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.
8
Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.
Oncogene. 2013 Jun 6;32(23):2873-81. doi: 10.1038/onc.2012.302. Epub 2012 Jul 16.
9
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Clin Cancer Res. 2015 Jul 1;21(13):2975-83. doi: 10.1158/1078-0432.CCR-15-0020. Epub 2015 Apr 2.
10
Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Sci Signal. 2014 Nov 11;7(351):ra107. doi: 10.1126/scisignal.2005516.
引用本文的文献
1
Quantitative measurement of phenotype dynamics during cancer drug resistance evolution using genetic barcoding.
Nat Commun. 2025 Jun 20;16(1):5282. doi: 10.1038/s41467-025-59479-7.
2
AP1-mediated reprogramming of EGFR expression triggers resistance to BLU-667 and LOXO-292 in RET-rearranged tumors.
J Exp Clin Cancer Res. 2025 May 22;44(1):154. doi: 10.1186/s13046-025-03392-w.
3
Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database.
Cancers (Basel). 2025 Feb 16;17(4):663. doi: 10.3390/cancers17040663.
4
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine.
Cell Death Dis. 2024 Oct 16;15(10):750. doi: 10.1038/s41419-024-07140-4.
5
The roles of patient-derived xenograft models and artificial intelligence toward precision medicine.
MedComm (2020). 2024 Sep 25;5(10):e745. doi: 10.1002/mco2.745. eCollection 2024 Oct.
6
Signaling dynamics in coexisting monoclonal cell subpopulations unveil mechanisms of resistance to anti-cancer compounds.
Cell Commun Signal. 2024 Jul 26;22(1):377. doi: 10.1186/s12964-024-01742-3.
7
Comparison of primary and passaged tumor cell cultures and their application in personalized medicine.
Explor Target Antitumor Ther. 2024;5(3):581-599. doi: 10.37349/etat.2024.00237. Epub 2024 Jun 17.
8
Mediator kinase inhibition impedes transcriptional plasticity and prevents resistance to ERK/MAPK-targeted therapy in KRAS-mutant cancers.
NPJ Precis Oncol. 2024 May 31;8(1):124. doi: 10.1038/s41698-024-00615-9.
9
Revolutionizing digestive system tumor organoids research: Exploring the potential of tumor organoids.
J Tissue Eng. 2024 May 27;15:20417314241255470. doi: 10.1177/20417314241255470. eCollection 2024 Jan-Dec.
10
MerTK Drives Proliferation and Metastatic Potential in Triple-Negative Breast Cancer.
Int J Mol Sci. 2024 May 8;25(10):5109. doi: 10.3390/ijms25105109.
本文引用的文献
1
Systematic identification of signaling pathways with potential to confer anticancer drug resistance.
Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877.
2
Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers.
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15964-8. doi: 10.1073/pnas.1412075111. Epub 2014 Oct 27.
3
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
Cancer Discov. 2014 Nov;4(11):1269-80. doi: 10.1158/2159-8290.CD-14-0462. Epub 2014 Oct 7.
4
TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity.
Oncotarget. 2014 Sep 30;5(18):8107-22. doi: 10.18632/oncotarget.2440.
5
Tumour heterogeneity and the evolution of polyclonal drug resistance.
Mol Oncol. 2014 Sep 12;8(6):1095-111. doi: 10.1016/j.molonc.2014.06.005. Epub 2014 Jul 10.
6
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.
Ann Oncol. 2014 Jul;25(7):1346-1355. doi: 10.1093/annonc/mdu141. Epub 2014 Apr 8.
7
Cancer: Clonal cooperation.
Nature. 2014 Apr 3;508(7494):52-3. doi: 10.1038/508052a.
8
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
Sci Transl Med. 2014 Feb 19;6(224):224ra26. doi: 10.1126/scitranslmed.3007947.
9
Detection of circulating tumor DNA in early- and late-stage human malignancies.
Sci Transl Med. 2014 Feb 19;6(224):224ra24. doi: 10.1126/scitranslmed.3007094.
10
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy.
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63. doi: 10.1038/nrm3722.
Zotero 插件